VanEck Vectors Generic Drugs ETF
GNRX
GNRX was delisted on the 4th of April, 2019.
4 hedge funds and large institutions have $732K invested in VanEck Vectors Generic Drugs ETF in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
155% more capital invested
Capital invested by funds: $287K → $732K (+$444K)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$248K |
| 2 |
Jane Street
New York
|
+$7.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$25.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $271K | +$7.83K | +336 | +3% |
|
|
2
Citadel Advisors
Miami,
Florida
| $259K | +$248K | +10,661 | New |
|
|
APA
3
American Portfolios Advisors
Holbrook,
New York
| $178K | +$170K | +7,311 | New |
|
4
Bank of America
Charlotte,
North Carolina
| $24K | – | – | – |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$25.3K | -1,141 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$1K | -50 | Closed |
|
GNRX Hedge Fund Activity: Q4 2017 in Review
4 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q4 2017, worth a combined $732K — up 155% from $287K a quarter earlier.
Fund positioning in GNRX was balanced in Q4 2017: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $248K. The largest seller was Federation des caisses Desjardins du Quebec, exiting entirely with an estimated $25.3K sold.
- 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $732K of VanEck Vectors Generic Drugs ETF stock for Q4 2017, up 155% quarter-over-quarter.
- 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q4 2017 and 2 closed out, a net change of 0 holders.
- The largest VanEck Vectors Generic Drugs ETF buyer in Q4 2017 was Citadel Advisors, an estimated $248K added.
- The largest VanEck Vectors Generic Drugs ETF seller in Q4 2017 was Federation des caisses Desjardins du Quebec, an estimated $25.3K sold.
Based on aggregated 13F filings for Q4 2017.